Entering text into the input field will update the search result below

Anavex Life Sci advances Alzheimer's candidate; shares up 27% premarket

Nov. 18, 2015 8:35 AM ETAnavex Life Sciences Corp. (AVXL) StockBy: Douglas W. House, SA News Editor17 Comments
  • Based on FDA guidance, Anavex Life Sciences (NASDAQ:AVXL) moves ahead with plans to conduct a Phase 2/3 clinical trial assessing ANAVEX 2-73 for the treatment of Alzheimer's disease.
  • According to the company, the pharmacokinetics/pharmacodynamics modeling completed in an earlier Phase 2a study will enable it to design the new Phase 2 in such a way as to minimize the risk of failure of the Phase 3. No word, though, on when the trial will commence.
  • Shares are up 27% premarket on robust volume.
  • Previously: Anavex 2-73 shows positive results in mid-stage Alzheimer's study; shares up 10% premarket (Nov. 9)

Recommended For You

About AVXL Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AVXL--
Anavex Life Sciences Corp.